The Creative Ways Drugmakers Are Delaying Generics
Drugmakers are increasingly embracing new tactics to protect billions of dollars in sales from generic competition. These strategies often involve patent trials, but that's not the only way companies are waylaying generic drugmakers.
In this clip from The Motley Fool's Industry Focus: Healthcare podcast, analyst Kristine Harjes and contributor Todd Campbell explain why companies like AbbVie (NYSE: ABBV) are working so hard to delay generic competition, how legal battles can add years of sales to drugs facing patent expiration, and how reformulating existing drugs to last longer helps keep sales flowing at companies like Teva Pharmaceutical (NYSE: TEVA).
A full transcript follows the video.
Source: Fool.com
Teva Pharmaceutical Industries Ltd ADR Stock
Teva Pharmaceutical Industries Ltd ADR is currently one of the favorites of our community with 17 Buy predictions and no Sell predictions.
As a result the target price of 18 € shows a slightly positive potential of 16.88% compared to the current price of 15.4 € for Teva Pharmaceutical Industries Ltd ADR.